Skip to main content

Table 4 Treatment-related adverse events in HCC patients with Lenvatinib monotherapy

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

Adverse event Any grade Grade I–II Grade III–V
Any adverse event 37/94.9% 26/66.7% 11/28.2%
Rash 2/5.1% 2/5.1% 0/0.00%
Diarrhea 7/18.0% 6/15.4% 1/2.6%
Anemia 13/33.3% 10/25.6% 3/7.7%
Elevated transaminase 18/46.2% 9/23.1% 9/23.1%
Hypertension 3/7.7% 3/7.7% 0/0.00%
Leukopenia 4/10.3% 4/10.3% 0/0.00%
Hypothyroidism 6/15.4% 6/15.4% 0/0.00%
Bleeding 6/15.4% 6/15.38% 0/0.00%
Proteinuria 12/30.8% 11/28.2% 1/2.6%
Fever 1/2.6% 1/2.6% 0/0.00%
Fatigue 7/18.0% 7/18.0% 0/0.00%
Hand-foot skin reaction 6/15.4% 6/15.4% 0/0.00%
Dysphonia 1/2.6% 1/2.6% 0/0.00%
Decreased appetite 3/7.7% 3/7.7% 0/0.00%
Vomitting 1/2.6% 1/2.6% 0/0.00%
  1. Data are presented as n/%